Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ: GMAB )

20.80 -0.42 (-1.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,120,114
Open 20.85
Bid (Size) 20.72 (1)
Ask (Size) 21.40 (1)
Prev. Close 21.22
Today's Range 20.75 - 21.02
52wk Range 19.85 - 31.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
Via Chartmill

Performance

YTD
-0.95%
-0.95%
1 Month
+3.20%
+3.20%
3 Month
-8.69%
-8.69%
6 Month
-25.18%
-25.18%
1 Year
-28.13%
-28.13%

More News

Read More
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via Chartmill
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB.
Via Chartmill
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
Via Chartmill
A Closer Look at 10 Analyst Recommendations For Genmab
Via Benzinga
Preview: Genmab's Earnings
Via Benzinga
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
12 Analysts Have This To Say About Genmab
Via Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
Via Chartmill
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
Via Chartmill
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
Via Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
Via Chartmill
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.